MeMed Ltd., a Tirat Carmel, Israel-based provider of a point of care platform that distinguishes bacterial from viral infections, has been awarded a $4,079,159 grant by the DoD’s Congressionally Directed Medical Research Programs (CDMRP).
The CDMRP grant, which complements a $9.2M contract from the Defense Threat Reduction Agency awarded last year, will support transition of the prototype point-of-care (POC) platform towards a final product, including transfer to manufacturing and implementation of cloud connectivity.
Led by Eran Eden, PhD, CEO, and Kfir Oved, MD/PhD, CTO, MeMed focuses on improving patient care through research, development and commercialization of solutions that decode the immune system’s distinct responses to different health and disease states.
The company focuses on providing rapid, accurate and actionable tests for acute infectious diseases and inflammatory disorders to be used in the hospital and community. Its first-generation test, ImmunoXpert, measures three blood borne immune markers to accurately detect whether a patient has a bacterial or viral infection, with the aim of empowering physicians to make more informed antibiotic treatment decisions. ImmunoXpert is cleared for clinical use in the EU (CE-IVD certified), Switzerland and Israel. It is currently in pilot distribution in these territories with a broader commercial roll-out underway.
MeMed’s second-generation test will provide rapid (within minutes) results at the point-of-care. The company is partnering with international stakeholders from industry and government to facilitate global availability of its tests.